Brind.

Third Avenue Management, an investment firm based in NYC, highlighted Supernus Pharmaceuticals as a stock pick.

3 reports, 2 independent Updated Aug 11
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Third Avenue Management, an investment firm based in NYC, highlighted Supernus Pharmaceuticals as a stock pick.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyHere’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small
  • Insider MonkeyShould You Consider Adding Champion Homes (SKY) to Your Portfolio? Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Real Estate Value Fund”
  • ZacksSupernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates Supernus Pharmaceuticals (SUPN) reported $165.45 million in revenue for the quarter ended June 2025, representing a year-